Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment
Immune checkpoint inhibitors (ICB) therapy have emerged as effective Display treatments for melanomas.However, the response of melanoma patients to ICB has been highly heterogenous.Here, by analyzing integrated scRNA-seq datasets from melanoma patients, we revealed significant differences in the TiME composition between ICB-resistant and responsive